我国核酸药物市场分析及对策建议

近年来,因兼具基因修饰和传统药物的双重特点,核酸药物已逐渐成为精准生物医学和疾病治疗的热点。为进一步推动我国核酸药物行业创新发展,采用定量分析和定性分析相结合的方法,对国内外核酸药物获批/授权、市场和研发情况进行分析,揭示全球ASO、siRNA、RNA aptamer及mRNA等四大类核酸药物的产业发展态势,系统梳理我国支持核酸药物创新发展的政策与措施,明确未来的技术主攻方向和应用潜力。面对国内基因治疗的迫切需求及核酸药物创制的严峻形势,研究提出推动源头创新、完善成果转移转化机制和营造良好竞争环境等对策建议。

Market Analysis and Countermeasures of Nucleic Acid Drugs in China

In recent years, due to the dual characteristics of genetic modification and traditional drugs, nucleic acid drugs have gradually attracted tremendous attention in the field of precision biomedicine and disease treatment. In order to further promote the innovation and development of nucleic acid drug industry of China, a combination of quantitative analysis and qualitative analysis have been used to analyze the situation of nucleic acid drugs of approval/authorization, market and research domestically and abroad. The results showed the global R&D status and industry development trends of four major categories of nucleic acid drugs: ASO, siRNA, RNA aptamer and mRNA. Besides, policies and measures to support the innovation and development of nucleic acid drugs in China, and the main direction of future technology and application potential have been sorted out and analyzed. Facing the urgent domestic demand for gene therapy and the severe situation in the innovation of nucleic acid drugs, countermeasures and suggestions have been put forward to promote innovation at the source, improve the mechanism for transfer and transformation of results, and create a good competitive environment.